

# Neyssa Marina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5839388/publications.pdf>

Version: 2024-02-01

114  
papers

12,110  
citations

41323

49  
h-index

29127

104  
g-index

162  
all docs

162  
docs citations

162  
times ranked

12242  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma—A population-based study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28998.	0.8	4
2	Osteosarcoma-Approach to Therapy. <i>Pediatric Oncology</i> , 2021, , 91-109.	0.5	10
3	Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. <i>Journal of Clinical Oncology</i> , 2021, 39, 4029-4038.	0.8	41
4	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , 2020, 2020, 1-6.	0.7	17
5	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2418-2426.	0.8	55
6	Maximum tumor dimension and tumor volume as prognostic factors in patients with newly diagnosed localized Ewing sarcoma (ES)- a report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11529-11529.	0.8	3
7	Genome-Informed Targeted Therapy for Osteosarcoma. <i>Cancer Discovery</i> , 2019, 9, 46-63.	7.7	245
8	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. <i>European Journal of Cancer</i> , 2019, 109, 36-50.	1.3	354
9	Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2529-2529.	0.8	12
10	Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. <i>JMIR Research Protocols</i> , 2019, 8, e14406.	0.5	4
11	How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1Âh: the Stanford Approach. <i>Molecular Imaging and Biology</i> , 2018, 20, 324-335.	1.3	29
12	Abstract PR05: Genomic analysis of osteosarcoma reveals opportunities for targeted therapy. , 2018, , .		0
13	Reply to Second malignancies in Ewing sarcoma survivors. <i>Cancer</i> , 2017, 123, 4075-4076.	2.0	0
14	Mortality in young adults with Ewing sarcoma treated at specialized cancer centers in California.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10538-10538.	0.8	1
15	Complete dexrazoxane cardioprotection for cardiac function but incomplete female cardioprotection for cardiac structure in doxorubicin-treated osteosarcoma survivors: Hearts too small for the body.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10519-10519.	0.8	0
16	Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1771-1779.	0.8	81
17	Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. <i>Journal of Surgical Oncology</i> , 2016, 113, 351-354.	0.8	10
18	Identification of Discrete Prognostic Groups in Ewing Sarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 47-53.	0.8	46

#	ARTICLE	IF	CITATIONS
19	Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 493-498.	0.8	23
20	Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11001-11001.	0.8	17
21	Racial/ethnic and socioeconomic disparities in survival among children with acute lymphoblastic leukemia in California, 1988-2011: A population-based observational study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1819-1825.	0.8	61
22	Tumoral <i>TP53</i> and/or <i>CDKN2A</i> alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 759-765.	0.8	39
23	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	3.0	152
24	Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report. <i>Sarcoma</i> , 2015, 2015, 1-8.	0.7	19
25	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2279-2287.	0.8	329
26	A summary of the osteosarcoma banking efforts: A report from the Children's Oncology Group and the QuadW Foundation. <i>Pediatric Blood and Cancer</i> , 2015, 62, 450-455.	0.8	19
27	A Genome-Wide Scan Identifies Variants in <i>NFIB</i> Associated with Metastasis in Patients with Osteosarcoma. <i>Cancer Discovery</i> , 2015, 5, 920-931.	7.7	88
28	Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient. <i>Pediatrics</i> , 2015, 136, e1377-e1381.	1.0	8
29	Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group. <i>Cancer</i> , 2015, 121, 467-475.	2.0	124
30	Congenital peribronchial myofibroblastic tumor: case report of an asymptomatic infant with a rapidly enlarging pulmonary mass and review of the literature. <i>Annals of Clinical and Laboratory Science</i> , 2015, 45, 83-9.	0.2	9
31	A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. <i>Cancer</i> , 2014, 120, 2448-2456.	2.0	158
32	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	1.4	90
33	Comparison of latino and non-Latino patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 233-237.	0.8	8
34	Symptom Assessment in Pediatric Oncology. <i>Cancer Nursing</i> , 2014, 37, 252-262.	0.7	36
35	HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1558-1564.	0.8	23
36	Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: A report of the children's oncology group (COG). <i>Pediatric Blood and Cancer</i> , 2013, 60, 1602-1605.	0.8	16

#	ARTICLE	IF	CITATIONS
37	Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group. <i>European Journal of Cancer</i> , 2013, 49, 2384-2391.	1.3	70
38	Changes in Health Status Among Aging Survivors of Pediatric Upper and Lower Extremity Sarcoma: A Report From the Childhood Cancer Survivor Study. <i>Archives of Physical Medicine and Rehabilitation</i> , 2013, 94, 1062-1073.	0.5	35
39	Genome-wide association study identifies two susceptibility loci for osteosarcoma. <i>Nature Genetics</i> , 2013, 45, 799-803.	9.4	181
40	Children's Oncology Group's 2013 blueprint for research: Bone tumors. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1009-1015.	0.8	164
41	A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. <i>Pediatric Blood and Cancer</i> , 2013, 60, 409-414.	0.8	55
42	Pediatric Acute Myeloid Leukemia as Classified Using 2008 WHO Criteria. <i>American Journal of Clinical Pathology</i> , 2013, 139, 818-825.	0.4	13
43	Treating pediatric osteosarcoma: recent clinical trial evidence. <i>Clinical Investigation</i> , 2013, 3, 967-978.	0.0	1
44	A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS10591-TPS10591.	0.8	1
45	MAP plus maintenance pegylated interferon $\hat{\pm}$ -2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response" randomization.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA10504-LBA10504.	0.8	14
46	Abstract 4593: Genome-wide association study identifies novel loci associated with osteosarcoma.. , 2013, , .		0
47	Utilization of subspecialty care by Hispanic pediatric oncology patients, California 1983-2010.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17504-e17504.	0.8	0
48	MAP plus maintenance pegylated interferon $\hat{\pm}$ -2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA10504-LBA10504.	0.8	4
49	Discordance of oncologic surgical classifications in COG studies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10528-10528.	0.8	0
50	Symptom Cluster Analyses Based on Symptom Occurrence and Severity Ratings Among Pediatric Oncology Patients During Myelosuppressive Chemotherapy. <i>Cancer Nursing</i> , 2012, 35, 19-28.	0.7	70
51	Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2545-2551.	0.8	204
52	Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2012, 59, 611-616.	0.8	13
53	Outcome for adolescent and young adult patients with osteosarcoma. <i>Cancer</i> , 2012, 118, 4597-4605.	2.0	153
54	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10081-10081.	0.8	3

#	ARTICLE	IF	CITATIONS
55	The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS).. Journal of Clinical Oncology, 2012, 30, 9503-9503.	0.8	6
56	Evaluation of local control strategies in patients with localized Ewing sarcoma of bone: A report from the Children's Oncology Group.. Journal of Clinical Oncology, 2012, 30, 9537-9537.	0.8	1
57	An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy. Supportive Care in Cancer, 2011, 19, 353-361.	1.0	37
58	Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2011, 57, 939-942.	0.8	36
59	Twenty years of follow-up of survivors of childhood osteosarcoma. Cancer, 2011, 117, 625-634.	2.0	91
60	High-intensity focused ultrasound (HIFU) is not indicated for treatment of primary bone sarcomas. Cancer, 2011, 117, 2822-2822.	2.0	9
61	Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors. Cancer, 2010, 116, 974-982.	2.0	7
62	Angiogenesis and vascular targeting in Ewing sarcoma. Cancer, 2010, 116, 749-757.	2.0	58
63	The role of interferons in the treatment of osteosarcoma. Pediatric Blood and Cancer, 2010, 54, 350-354.	0.8	57
64	Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group. Clinical Cancer Research, 2010, 16, 4024-4030.	3.2	72
65	Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions in Ewing Sarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2010, 28, 1989-1994.	0.8	138
66	Changes in Children's Reports of Symptom Occurrence and Severity During a Course of Myelosuppressive Chemotherapy. Journal of Pediatric Oncology Nursing, 2010, 27, 307-315.	1.5	111
67	Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2009, 27, 2536-2541.	0.8	294
68	Multiple Symptoms in Pediatric Oncology Patients: A Systematic Review. Journal of Pediatric Oncology Nursing, 2009, 26, 325-339.	1.5	71
69	Immune approaches to treating osteosarcoma. Cancer Biology and Therapy, 2009, 8, 981-983.	1.5	6
70	Physical Performance Limitations in the Childhood Cancer Survivor Study Cohort. Journal of Clinical Oncology, 2009, 27, 2382-2389.	0.8	154
71	Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2009, 52, 324-327.	0.8	67
72	Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with wilms tumour. European Journal of Cancer, 2009, 45, 99-106.	1.3	38

#	ARTICLE	IF	CITATIONS
73	Anti-insulin growth factor receptor therapy in Ewing sarcoma. F1000 Medicine Reports, 2009, 1, .	2.9	3
74	Complementary and alternative therapy use in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Pediatric Blood and Cancer, 2008, 50, 90-97.	0.8	31
75	Application of the adult International Germ Cell Classification System to pediatric malignant nonâ€seminomatous germ cell tumors: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2008, 50, 746-751.	0.8	34
76	Imaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committee. Pediatric Blood and Cancer, 2008, 51, 163-170.	0.8	164
77	Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multiâ€modality therapy: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2008, 51, 334-338.	0.8	164
78	Response to â€œimaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committeeâ€• Pediatric Blood and Cancer, 2008, 51, 839-840.	0.8	3
79	Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976. Cancer, 2008, 113, 2597-2604.	2.0	55
80	Osteosarcoma: The Same Old Drugs or More?. Journal of Clinical Oncology, 2008, 26, 3102-3103.	0.8	62
81	Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics, 2008, 121, e387-e396.	1.0	248
82	Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors. Journal of Clinical Oncology, 2007, 25, 3635-3643.	0.8	109
83	Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer, 2007, 110, 2385-2393.	2.0	161
84	Prognostic Factors in Children With Extragenital Malignant Germ Cell Tumors: A Pediatric Intergroup Study. Journal of Clinical Oncology, 2006, 24, 2544-2548.	0.8	76
85	Chronic Health Conditions in Adult Survivors of Childhood Cancer. New England Journal of Medicine, 2006, 355, 1572-1582.	13.9	3,111
86	Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors. Cancer, 2005, 104, 841-847.	2.0	98
87	Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells. Clinical Cancer Research, 2005, 11, 4561-4570.	3.2	30
88	High-Dose Therapy and Stem-Cell Rescue for Ewing's Family of Tumors in Second Remission. Journal of Clinical Oncology, 2005, 23, 4262-4264.	0.8	13
89	Treatment of Children and Adolescents With Stage II Testicular and Stages I and II Ovarian Malignant Germ Cell Tumors: A Pediatric Intergroup Studyâ€• Pediatric Oncology Group 9048 and Children's Cancer Group 8891. Journal of Clinical Oncology, 2004, 22, 3563-3569.	0.8	152
90	Biology and Therapeutic Advances for Pediatric Osteosarcoma. Oncologist, 2004, 9, 422-441.	1.9	604

#	ARTICLE	IF	CITATIONS
91	Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline. <i>Journal of Clinical Oncology</i> , 2004, 22, 4979-4990.	0.8	626
92	Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Studyâ€”Pediatric Oncology Group 9049 and Children's Cancer Group 8882. <i>Journal of Clinical Oncology</i> , 2004, 22, 2691-2700.	0.8	221
93	Health Status of Adult Long-term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 1583-1592.	3.8	720
94	Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. <i>Clinical Cancer Research</i> , 2003, 9, 5442-53.	3.2	135
95	Abnormalities of the Thyroid in Survivors of Hodgkinâ€™s Disease: Data from the Childhood Cancer Survivor Study<sup>1</sup>. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3227-3232.	1.8	313
96	Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: A report of the Pediatric Oncology Group and the Childrenâ€™s Cancer Group. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 181, 353-358.	0.7	160
97	Peritoneal metastases in children with cancer. , 1998, 83, 385-390.		14
98	Wilms?? Tumour. <i>Drugs</i> , 1998, 56, 597-605.	4.9	18
99	Nongestational Choriocarcinoma in the Postpartum Period. <i>Journal of Pediatric Hematology/Oncology</i> , 1998, 20, 169-173.	0.3	7
100	Comparison of Cytokines in Children with Recurrent Solid Tumors Treated with Intensive Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 1998, 20, 62-68.	0.3	7
101	LONG-TERM SURVIVORS OF CHILDHOOD CANCER. <i>Pediatric Clinics of North America</i> , 1997, 44, 1021-1042.	0.9	105
102	Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 41, 229-236.	1.1	1
103	Phase I trial of subcutaneous interleukin-1Î± in children with malignant solid tumors. , 1997, 28, 444-450.		8
104	Cytomegalovirus causing pericarditis with tamponade in an adolescent with cancer. , 1996, 26, 70-70.		2
105	Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: A single hospital experience. , 1996, 27, 145-148.		12
106	Local control in synchronous bilateral Wilms tumor. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 36, 541-548.	0.4	38
107	A phase I study of sulofenur in refractory pediatric malignant solid tumors. <i>Investigational New Drugs</i> , 1995, 13, 63-66.	1.2	7
108	Primary malignancy of the salivary gland in children. <i>Journal of Pediatric Surgery</i> , 1994, 29, 44-47.	0.8	51

#	ARTICLE	IF	CITATIONS
109	Response of immunocompromised children with solid tumors to a conjugate vaccine for Haemophilus influenzae type b. <i>Journal of Pediatrics</i> , 1994, 125, 581-584.	0.9	20
110	Lack of heritability in ovarian germ cell malignancies. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 170, 1803-1808.	0.7	12
111	Progress in the treatment of adolescents with acute lymphoblastic leukemia. <i>Cancer</i> , 1993, 71, 3400-3405.	2.0	24
112	A phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors. <i>Cancer</i> , 1993, 71, 3661-3665.	2.0	15
113	Use of HBA 71 and anti-Î²2-microglobulin to distinguish peripheral neuroepithelioma from neuroblastoma. <i>Human Pathology</i> , 1993, 24, 880-885.	1.1	39
114	Treatment of childhood germ cell tumors: Review of the St. Jude experience from 1979 to 1988. <i>Cancer</i> , 1992, 70, 2568-2575.	2.0	72